12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Trametinib: Phase III started

GlaxoSmithKline began the double-blind, placebo-controlled, international Phase III COMBI-AD trial to evaluate twice-daily 150 mg oral dabrafenib ( GSK2118436) plus once-daily 2 mg oral trametinib for 12 months in about 850 patients with stage IIIa, IIIb or IIIc melanoma. Last August, GSK submitted regulatory applications for dabrafenib and trametinib, including NDAs...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >